Core Insights - Treace Medical Concepts, Inc. reported a 10% increase in revenue for Q4 2024, reaching $68.7 million, compared to $62.2 million in Q4 2023, driven by product mix shift and increased adoption of newer technologies [4][10] - The company achieved a gross profit of $55.5 million in Q4 2024, with a gross margin of 80.7%, slightly down from 81.6% in Q4 2023 [5][10] - For the full year 2024, revenue was $209.4 million, a 12% increase from $187.1 million in 2023, with a gross profit of $168.3 million [8][10] - The net loss for Q4 2024 was reduced to $0.5 million, or $0.01 per share, compared to a net loss of $6.3 million, or $0.10 per share, in Q4 2023 [7][10] - The company expects full-year 2025 revenue to be between $224 million and $230 million, indicating growth of 7% to 10% compared to 2024 [13] Financial Performance - Q4 2024 operating expenses decreased to $55.7 million from $57.5 million in Q4 2023, reflecting improved leverage in Sales & Marketing [6][10] - Adjusted EBITDA for Q4 2024 was $11.1 million, a significant increase of 322% from $2.6 million in Q4 2023 [7][10] - Full-year 2024 net loss was $55.7 million, or $0.90 per share, compared to a net loss of $49.5 million, or $0.81 per share, in 2023 [9][10] Strategic Developments - The company announced its entry into the high-volume osteotomy market with the introduction of Nanoplasty™ and Percuplasty™ Minimally Invasive 3D Bunion Systems [10] - Treace added 280 new active surgeons in 2024, bringing the total to 3,135, a 10% increase year-over-year [10] - The global patent portfolio expanded to 97 granted patents and 88 pending applications, enhancing the company's competitive position [10] Cash Position - As of December 31, 2024, cash, cash equivalents, and marketable securities totaled $75.7 million, with access to an additional $26 million through an existing revolver, bringing the total to approximately $102 million [12]

Core Insights - Treace Medical Concepts, Inc. will release its financial results for Q4 and full year 2024 on February 27, 2025, after market close [1] - A conference call will be held at 4:30 pm ET to discuss these results [1] Company Overview - Treace Medical Concepts is focused on advancing surgical treatment for bunions and midfoot deformities through its Lapiplasty® and Adductoplasty® procedures [4] - Approximately 67 million Americans are affected by bunions, with an estimated 1.1 million being surgical candidates annually [4] - The company has developed the Lapiplasty® 3D Bunion Correction® System, which addresses the root cause of bunions by correcting deformities in three planes [4] - Treace has also introduced the Adductoplasty® Midfoot Correction System for midfoot deformities and the SpeedPlate™ Rapid Compression Implants for various foot procedures [4]

Core Insights - Treace Medical Concepts, Inc. has successfully completed the first cases utilizing its SpeedAkin™ Anatomic Compression Implant, enhancing its surgical treatment offerings for bunions and related midfoot deformities [1][2]. Company Overview - Treace Medical Concepts is focused on advancing the standard of care for surgical management of bunions and midfoot deformities, which affect approximately 67 million Americans, with an estimated 1.1 million being annual surgical candidates [6]. - The company has pioneered the Lapiplasty® 3D Bunion Correction® System, which addresses the root cause of bunions by correcting all three planes of the deformity [6]. Product Development - The SpeedAkin™ implant enhances the procedural versatility of the SpeedPlate™ fixation platform, which is designed to set a new standard in bone fusion fixation [2]. - The SpeedAkin™ implant provides dynamic titanium compression to stabilize Akin osteotomies during healing, which are corrective procedures often performed alongside bunion surgeries [2][3]. Surgeon Feedback - Surgeons, such as Amber Shane, have noted that the SpeedAkin™ titanium compression implant offers anatomically contoured fixation and eliminates the risk of nickel allergy associated with nitinol staples, marking a significant advancement for Lapiplasty® and Adductoplasty® procedures [4].

Core Viewpoint - Treace Medical Concepts, Inc. (TMCI) shareholders may have been impacted by potential fraudulent activities, prompting an investigation by Levi & Korsinsky [1] Group 1: Company Overview - Treace Medical Concepts, Inc. is under scrutiny for possible fraud that could affect its shareholders [1] - The investigation is being conducted by the law firm Levi & Korsinsky, which specializes in shareholder rights [1] Group 2: Investigation Details - The investigation aims to determine if TMCI misled investors regarding its business practices and financial performance [1] - Shareholders are encouraged to reach out to the law firm to discuss their rights and potential claims [1]

The Schall Law Firm Invites Shareholders With Losses To Join An Inquiry Into Treace Medical Concepts, Inc. For Securities Law Violations ...

Company Investigation - Levi & Korsinsky is investigating whether Treace Medical Concepts Inc (TMCI) misled investors [1] - The investigation focuses on potential misleading statements or omissions by the company [1] - Shareholder rights advocates are involved in the probe [1] Legal Context - The investigation is being conducted by a law firm specializing in shareholder rights [1] - The probe is in its early stages with no conclusions yet [1] - The investigation could potentially lead to legal action if wrongdoing is found [1]

Core Viewpoint - Treace Medical Concepts, Inc. is under investigation for potential violations of securities laws, prompting affected investors to reach out to the Schall Law Firm for assistance [1] Group 1 - The investigation into Treace Medical Concepts, Inc. suggests possible legal issues that could impact the company's reputation and financial standing [1] - Affected investors are encouraged to contact legal representation, indicating a significant concern regarding the company's compliance with securities regulations [1]

The Schall Law Firm Invites Shareholders With Losses To Join An Inquiry Into Treace Medical Concepts, Inc. For Securities Fraud ...

Financial Results - Treace Medical Concepts, Inc. reported preliminary unaudited financial results for the quarter and year ended December 31, 2024[7]. Upcoming Events - The company plans to present at the J.P. Morgan Healthcare Conference on January 14, 2025, at 9:00 am Pacific Time[9]. - An investor presentation was posted on the company's investor relations website on January 13, 2025[9].

PONTE VEDRA, Fla., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced its preliminary, unaudited fourth quarter and full-year 2024 results. Highlights: Preliminary revenue of $68.4 million to $68.8 million in the fourth quarter of 2024, an approxi ...